"Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)." by Alain Patrick Algazi

Selected Works of Carlo B. Bifulco, M.D.

Article

Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).

Journal of Clinical Oncology (2017)

Alain Patrick Algazi, University of California, San Francisco
Katy K. Tsai, University of California, San Francisco
Michael Rosenblum, University of California, San Francisco
Bernard A. Fox, Providence Portland Medical Center
Robert Hans Ingemar Andtbacka, Huntsman Cancer Institute
Amy Li, University of California, San Francisco
Kathryn Toshimi Takamura, Oncosec Medical Inc., San Diego, CA;
Mary Dwyer, Oncosec Medical Inc., San Diego, CA;
Erica Browning, Oncosec Medical Inc., San Diego, CA;
Reneta Talia, Oncosec Medical Inc., San Diego, CA;
Chris Twitty, Oncosec Medical Inc., San Diego, CA;
Mai H. Le, Oncosec Medical Inc., San Diego, CA;
Sharron Gargosky, Oncosec Medical Inc., San Diego, CA;
Jean S. Campbell, Oncosec Medical Inc., San Diego, CA;
Carmen Ballesteros-Merino, Providence Portland Medical Center
Carlo Bruno Bifulco, Providence Portland Medical Center
Robert Pierce, Oncosec Medical Inc., San Diego, CA;
Adil Daud, University of California, San Francisco

Link

Disciplines

Publication Date

March 1, 2017

DOI

10.1200/JCO.2017.35.7_SUPPL.78

Citation Information

Alain Patrick Algazi, Katy K. Tsai, Michael Rosenblum, Bernard A. Fox, et al.. "Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)." Journal of Clinical Oncology Vol. 35 (2017) p. 78 - 78
Available at: http://works.bepress.com/carlo-bifulco/75/